[go: up one dir, main page]

MX2016008898A - Antagonistas selectivos de nr2b. - Google Patents

Antagonistas selectivos de nr2b.

Info

Publication number
MX2016008898A
MX2016008898A MX2016008898A MX2016008898A MX2016008898A MX 2016008898 A MX2016008898 A MX 2016008898A MX 2016008898 A MX2016008898 A MX 2016008898A MX 2016008898 A MX2016008898 A MX 2016008898A MX 2016008898 A MX2016008898 A MX 2016008898A
Authority
MX
Mexico
Prior art keywords
compounds
nr2b antagonists
selective nr2b
selective
antagonists
Prior art date
Application number
MX2016008898A
Other languages
English (en)
Inventor
Islam Imadul
E Macor John
King Dalton
A Thompson Lorin Iii
Shi Jianliang
Thangathirupathy Srinivasan
Sankara Warrier Jayakumar
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2016008898A publication Critical patent/MX2016008898A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La descripción se refiere generalmente a compuestos de la fórmula I, incluyendo sus sales, así como composiciones y métodos de uso de los compuestos. Los compuestos son ligandos del receptor NR2B y pueden ser útiles para el tratamiento de diversos trastornos del sistema nervioso central.
MX2016008898A 2014-01-09 2015-01-06 Antagonistas selectivos de nr2b. MX2016008898A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461925363P 2014-01-09 2014-01-09
PCT/US2015/010262 WO2015105772A1 (en) 2014-01-09 2015-01-06 Selective nr2b antagonists

Publications (1)

Publication Number Publication Date
MX2016008898A true MX2016008898A (es) 2016-10-04

Family

ID=52463126

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016008898A MX2016008898A (es) 2014-01-09 2015-01-06 Antagonistas selectivos de nr2b.

Country Status (28)

Country Link
US (10) US9221796B2 (es)
EP (1) EP3092224B1 (es)
JP (1) JP6543259B2 (es)
KR (1) KR102311518B1 (es)
CN (1) CN106061961B (es)
AR (1) AR099071A1 (es)
AU (1) AU2015205001A1 (es)
CA (1) CA2936293A1 (es)
CL (1) CL2016001763A1 (es)
DK (1) DK3092224T3 (es)
EA (1) EA201691413A1 (es)
ES (1) ES2693250T3 (es)
HR (1) HRP20181585T1 (es)
HU (1) HUE041986T2 (es)
IL (1) IL246599A0 (es)
LT (1) LT3092224T (es)
MX (1) MX2016008898A (es)
PE (1) PE20160933A1 (es)
PL (1) PL3092224T3 (es)
PT (1) PT3092224T (es)
RS (1) RS57830B1 (es)
SG (1) SG11201605618WA (es)
SI (1) SI3092224T1 (es)
SM (1) SMT201800619T1 (es)
TR (1) TR201815579T4 (es)
TW (1) TWI640515B (es)
UY (1) UY35947A (es)
WO (1) WO2015105772A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9221796B2 (en) * 2014-01-09 2015-12-29 Bristol-Myers Squibb Company Selective NR2B antagonists
JP6876625B2 (ja) * 2015-06-01 2021-05-26 リューゲン ホールディングス （ケイマン） リミテッド Ｎｒ２ｂｎｍｄａレセプターアンタゴニストとしての３，３−ジフルオロピペリジンカルバメート複素環式化合物
EA201890946A1 (ru) * 2015-10-14 2018-09-28 Бристол-Маерс Сквибб Компани Селективные антагонисты nr2b
CA3001894A1 (en) 2015-10-14 2017-04-20 Bristol-Myers Squibb Company Selective nr2b antagonists
US11000526B2 (en) 2016-11-22 2021-05-11 Rugen Holdings (Cayman) Limited Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders
CN108203404A (zh) * 2018-03-02 2018-06-26 上海博邦医药科技有限公司 (r)-3-苯基哌啶或/和(s)-3-苯基哌啶以及尼拉帕尼的手性中间体的合成方法
US10781172B2 (en) 2018-06-21 2020-09-22 Northwestern University Catalysts and methods for enantioselective conjugate additions of amines to unsaturated electrophiles
WO2024197289A1 (en) * 2023-03-22 2024-09-26 Gilgamesh Pharmaceuticals, Inc. Negative allosteric modulators of glun2b receptors and methods of making and using the same
WO2025113519A1 (zh) * 2023-11-28 2025-06-05 成都地奥制药集团有限公司 内酰胺环类化合物及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2744448B1 (fr) 1996-02-02 1998-04-24 Pf Medicament Nouvelles piperidines derivees d'aryl piperazine, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
WO2000063173A1 (en) 1999-04-14 2000-10-26 F. Hoffmann-La Roche Ag Process for the preparation of substituted piperidines
US6476041B1 (en) 1999-10-29 2002-11-05 Merck & Co., Inc. 1,4 substituted piperidinyl NMDA/NR2B antagonists
KR20020093950A (ko) * 2000-04-26 2002-12-16 워너-램버트 캄파니 아형 선택적인 ｎｍｄａ 수용체 길항제로서의시클로헥실아민 유도체
WO2003035641A1 (en) 2001-10-22 2003-05-01 Shionogi & Co., Ltd. Novel carbamoylpyrrolidone derivative
MXPA05013151A (es) 2003-06-04 2006-03-17 Merck & Co Inc 3-fluoro-piperidinas como antagonistas de n-metil-d-aspartato/nr2b.
JP2007508288A (ja) 2003-10-08 2007-04-05 ファイザー株式会社 縮合ラクタム化合物
US7935706B2 (en) 2006-02-23 2011-05-03 Shionogi & Co., Ltd. Nitrogen-containing heterocycle derivatives substituted with cyclic group
CN101815518B (zh) * 2007-06-29 2013-01-09 埃莫里大学 用于神经保护的nmda受体拮抗剂
US9221796B2 (en) * 2014-01-09 2015-12-29 Bristol-Myers Squibb Company Selective NR2B antagonists

Also Published As

Publication number Publication date
US20210121453A1 (en) 2021-04-29
US20180000807A1 (en) 2018-01-04
CN106061961A (zh) 2016-10-26
LT3092224T (lt) 2018-10-25
US20200163949A1 (en) 2020-05-28
JP2017502063A (ja) 2017-01-19
US9221796B2 (en) 2015-12-29
US20180250283A1 (en) 2018-09-06
SI3092224T1 (sl) 2018-11-30
CA2936293A1 (en) 2015-07-16
US20190117638A1 (en) 2019-04-25
US20180110766A1 (en) 2018-04-26
AU2015205001A1 (en) 2016-08-18
WO2015105772A1 (en) 2015-07-16
JP6543259B2 (ja) 2019-07-10
SG11201605618WA (en) 2016-08-30
TR201815579T4 (tr) 2018-11-21
PE20160933A1 (es) 2016-09-10
EP3092224A1 (en) 2016-11-16
IL246599A0 (en) 2016-08-31
PT3092224T (pt) 2018-11-14
RS57830B1 (sr) 2018-12-31
US20160081995A1 (en) 2016-03-24
TWI640515B (zh) 2018-11-11
UY35947A (es) 2015-07-31
AR099071A1 (es) 2016-06-29
CN106061961B (zh) 2018-12-18
US20150191452A1 (en) 2015-07-09
TW201613884A (en) 2016-04-16
KR20160105885A (ko) 2016-09-07
ES2693250T3 (es) 2018-12-10
HUE041986T2 (hu) 2019-06-28
KR102311518B1 (ko) 2021-10-08
US20190314358A1 (en) 2019-10-17
US20170258777A1 (en) 2017-09-14
PL3092224T3 (pl) 2019-05-31
CL2016001763A1 (es) 2017-02-10
HRP20181585T1 (hr) 2018-12-14
EA201691413A1 (ru) 2016-10-31
DK3092224T3 (en) 2018-11-26
SMT201800619T1 (it) 2019-01-11
EP3092224B1 (en) 2018-08-22

Similar Documents

Publication Publication Date Title
MX2016008898A (es) Antagonistas selectivos de nr2b.
MX2016005759A (es) Derivados de piridina sustituidos, utiles como inhibidores de glucogeno sintasa cinasa 3 (gsk-3).
NZ737399A (en) Ccr2 modulators
MX2021014128A (es) Polimorfos de selinexor.
PH12016501966A1 (en) Compounds and compositions as toll-like receptor 7 agonists
NZ724878A (en) Compounds and compositions as toll-like receptor 7 agonists
MX379110B (es) Derivados de azaspiro como antagonistas de trpm8.
MX2016005760A (es) Inhibidores de glucogeno sintasa cinasa 3 (gsk-3).
EA201791058A1 (ru) Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4)
MX2018000352A (es) 4-azaindoles sustituidos y su uso como moduladores del receptor glun2b.
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
PH12017500089B1 (en) Aldosterone synthase inhibitors
EA201890764A1 (ru) Селективные антагонисты nr2b
TW201612160A (en) Compounds as CRTH2 antagonist and uses thereof
PH12016501393A1 (en) Substituted bicyclic heteroaryl compounds as rxr agonists
MD4780B1 (ro) Urei asimetrice p-substituite şi utilizările medicale ale acestora
MX2020009966A (es) Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina.
TW201612169A (en) (R)-3-((3s,4s)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders
MX2018004256A (es) Antagonistas de receptor de n-metil-d-aspartato subtipo 2b (nr2b) selectivos.
WO2013048949A3 (en) Selective nr2b antagonists
MX2015000064A (es) Compuestos de acrilamida como ligandos receptores de histamina h3.
GB2564185A (en) Process for the preparation of derivatives of benzodioxole
IN2013CH01199A (es)
MX2016010549A (es) Indol- y bencimidazolcarboxamidas como insecticidas y acaricidas.